Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $20.60.
A number of brokerages have commented on MSLE. Craig Hallum began coverage on Satellos Bioscience in a report on Thursday, October 8th. They set a “buy” rating and a $24.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Satellos Bioscience in a research note on Monday, August 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Zacks Research downgraded Satellos Bioscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 21st.
Get Our Latest Research Report on Satellos Bioscience
Satellos Bioscience Stock Down 2.4%
Shares of NASDAQ MSLE opened at $6.47 on Tuesday. The firm has a market cap of $137.29 million, a price-to-earnings ratio of -3.10 and a beta of 1.63. The company’s 50-day simple moving average is $7.72 and its 200-day simple moving average is $8.18. Satellos Bioscience has a 52-week low of $5.44 and a 52-week high of $13.39.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Equities research analysts anticipate that Satellos Bioscience will post -1.86 EPS for the current fiscal year.
Institutional Investors Weigh In On Satellos Bioscience
A hedge fund recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC increased its holdings in shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 391.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 491,624 shares of the company’s stock after acquiring an additional 391,624 shares during the quarter. Satellos Bioscience comprises 0.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 2.36% of Satellos Bioscience worth $3,723,291 as of its most recent SEC filing.
Satellos Bioscience Company Profile
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
Featured Stories
- Five stocks we like better than Satellos Bioscience
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
